ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...

Jeffrey Weiss is fitted with an Optune device as part of his treatment for glioblastoma at his home in North Dallas on April 12. Louis DeLuca / Staff Photographer I'm now more than six months into the ...

Shares soar in response to the release of positive clinical updates. NovoCure gave a series of clinical updates that got the markets excited. First, the company reported data from its phase 2 Panova ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...

NovoCure recently secured approval for its Optune Lua® device in Japan, a milestone for the company’s TTFields therapy that targets non-small cell lung cancer. This development aligns with the company ...

Tumor-treating fields (TTFields) are a relatively new form of cancer treatment that send mild electrical fields through the scalp in an effort to block cell division. While it was approved a few years ...

CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers ...

Novocure has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the use of its portable Optune Lua device alongside PD-1/PD-L1 inhibitors to treat non-small cell lung ...

A wearable device that uses electricity to disrupt cancer cells has improved survival for people with brain cancer for the first time in more than a decade. Joyce Endresen often gets asked what is on ...

As a particularly aggressive brain tumor, it almost goes without saying that glioblastomas are scary things. Fortunately, patients are benefiting from a new technology that has only been available to ...